Sign in

    David A. Ricks

    Chair, President, and Chief Executive Officer at Eli Lilly and Co
    Board
    Since 2017
    Age
    57 years
    Tenure
    Has been with LLY for 28 years, starting in 1996 and progressing through roles in marketing, sales, international leadership, as President of Lilly USA, and as Senior Vice President & President of Lilly Bio-Medicines before being named Chair, President, and CEO in 2017.

    Also at Eli Lilly and Co

    AW
    Alonzo Weems
    Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
    AH
    Anat Hakim
    Executive Vice President, General Counsel, and Secretary
    AW
    Anne White
    Executive Vice President and President of Lilly Neuroscience

    About

    David A. Ricks serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company, bringing a wealth of experience from a 28-year career at the firm. At 57 years old as of 2024 , his leadership reflects decades of service and strategic guidance across various divisions of the company.

    Throughout his distinguished career, he has held key roles including positions in marketing, sales, and international operations, progressing from significant leadership roles such as President of Lilly USA and Senior Vice President & President of Lilly Bio-Medicines to ultimately leading the company as CEO in 2017.

    In addition to his executive roles at LLY, he contributes to the broader industry by serving on the board of directors for Adobe Inc. and participating in several industry organizations such as the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers & Associations.

    $LLY Performance Under David A. Ricks

    Past Roles

    Organization Role Date Range Details [N/A]
    Eli Lilly and Company Senior Vice President and President, Lilly Bio-Medicines 2012–2016 N/A
    Eli Lilly and Company President, Lilly USA 2009–2012 N/A
    Eli Lilly and Company President and General Manager, Lilly China 1996–2009 N/A
    Eli Lilly and Company General Manager, Lilly Canada 1996–2009 N/A

    External Roles

    Organization Role Date Range Details [N/A]
    Adobe Inc. Director N/A N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$1,621,154 Annually (2023)Fixed base salary
    Nonqualified Savings Plan Contributions$77,469 Annually (2023)Employer contribution
    401(k) Contributions$19,800 Annually (2023)Derived from total matching contributions of $97,269 minus Nonqualified Savings Plan Contributions
    Personal Use of Corporate Aircraft$65,804 Annually (2023)Incremental cost for personal use
    HSR Filing Fee Reimbursement$100,000 Annually (2023)Reimbursed fee processed as imputed income for tax withholding

    Performance Compensation

    Data from  FY 2023

    Non-Equity Incentive Plan Compensation (Bonus Plan)

    Metric [Weight] (%)Target/Threshold DetailActual Result/MultiplierPayout Amount (USD)
    Revenue [25%]Not explicitly provided––
    EPS [50%]Target: 2.0% annual growth (cumulative goal not detailed) ––
    Pipeline Progress [25%]Targets include: 2 new drug first approvals; 9 other approvals (among other metrics) Pipeline multiple: 1.86 –
    Overall BonusPayout Multiple: 181% of target –$4,401,433
    Evaluation Period: Annual 2023; no vesting as award is cash-based

    2023-2025 Performance Awards (EPS-Based)

    Metric [Detail]ValueNotes
    Grant DateFeb 10, 2023 –
    Grant Date Fair Value (USD)$6,327,750 Determined at grant date
    Performance MetricEPS GrowthAssessed via cumulative 2-year EPS performance
    Threshold Shares7,983 0% payout if cumulative EPS ≤ $16.12
    Target Shares15,966 100% payout if cumulative EPS = $18.21
    Maximum Shares31,932 200% payout if cumulative EPS ≥ $21.57
    Vesting ScheduleFebruary 2026 Contingent upon meeting employment requirements

    2023-2025 Shareholder Value Awards (SVA)

    Metric [Detail]ValueNotes
    Grant DateFeb 10, 2023 –
    Grant Date Fair Value (USD)$6,256,250 –
    Weighted-Average Fair Value (USD)$349.63 Derived via Monte Carlo simulation
    Performance MetricFinal Stock PriceBased on 3-year stock performance
    Payout ThresholdFinal Price < $347.53 Results in 0% payout
    Payout TargetFinal Price = $441.12 100% payout
    Payout MaximumFinal Price > $584.73 200% payout
    Target Shares19,512 –
    Maximum Shares39,024 200% of target
    Vesting ScheduleDecember 31, 2025 Subject to a one-year post-vesting holding requirement

    2023-2025 Relative Value Awards (RVA)

    Metric [Detail]ValueNotes
    Grant DateFeb 10, 2023–
    Grant Date Fair Value (USD)$6,256,250 –
    Performance MetricRelative TSR vs. peer groupAssesses total shareholder return relative to peers
    Payout Threshold≤ -24.0 pp difference Yields 0% payout
    Payout TargetAt Peer Median TSR Yields 100% payout
    Payout Maximum≥ +30.0 pp difference Yields 200% payout
    Target Shares15,721 –
    Maximum Shares31,442 200% of target
    Vesting ScheduleDecember 31, 2025 Contingent on continued employment